Current Headlines

  1. New Chronic Lymphocytic Leukemia Therapy Enters Phase 1 Trial`
    9/19/2014

    Researchers at the University of California, San Diego School of Medicine have just moved their novel monoclonal antibody called cirmtuzumab (UC-961) into a phase 1 human clinical trial for treating chronic lymphocytic leukemia (CLL).

  2. Puerto Rico To Be New Hub For HIV Vaccine R&D
    9/19/2014

    Puerto Rico is set to become the center of research and development activities for HIV/AIDS, thanks to a multi-stakeholder collaboration that will be attempting to produce a prophylactic vaccine against the infection.

  3. Pfizer, MedGenesis’ Team Up To Explore Potential Parkinson’s Treatments
    9/19/2014

    Biotech firm MedGenesis Therapeutix announced that it has agreed to grant Pfizer an exclusive, global option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology for research as treatment for Parkinson's disease.

  4. Novo Nordisk’s Tresiba Shows Efficacy In Children With T1 Diabetes
    9/19/2014

    Novo Nordisk’s Tresiba (insulin degludec) demonstrated its effective in children aged 1 to 18 with Type 1 diabetes. The company announced results from the BEGIN YOUNG 1 trial in a press release and at a meeting of the European Association for the Study of Diabetes (EASD). The once-daily basal insulin is approved in over 30 countries but not in the U.S., as the Food and Drug Administration (FDA) has thus far declined to approve it, citing concerns regarding cardiovascular outcomes.

  5. NW Bio’s Cancer Vaccine First To Receive PIM Designation In U.K.’s Early Access Scheme
    9/19/2014

    Northwest Biotherapeutics (NW) announced that its new cancer immune therapy, DCVax-L, is the first drug to receive “Promising Innovative Medicine” (PIM) designation by the U.K.’s new “Early Access to Medicines Scheme” (EAMS). Like the U.S.’s compassionate use program, the EAMS aims to get urgently needed drug therapies to patients more quickly.

  6. Sun Pharma Licenses Merck’s Psoriasis Drug For $80M
    9/18/2014

    Merck announced that it has entered into a licensing agreement with Indian generics company Sun Pharmaceuticals for Merck’s therapeutic antibody candidate tildrakizumab as treatment for chronic plaque psoriasis.

  7. Mylan, Gilead Partner To Bring Cheaper Hepatitis C Treatment To Developing Countries
    9/18/2014

    In a new collaboration with Gilead Sciences, Mylan has won the nonexclusive rights to manufacture and distribute sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir in 91 developing countries. Gilead currently markets Sovaldi, the brand-name version of sofosbuvir, indicated for those with hepatitis C.

  8. Biogen Idec Announces Strides In Clinical Studies For MS Treatments
    9/18/2014

    Biogen Idec announced clinical study results for three of its Multiple Sclerosis (MS) treatments at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis in Boston last week.

  9. EMD Serono, Sutro Biopharma Form ADC Partnership
    9/18/2014

    EMD Serono, a subsidiary of Merck, and Sutro Biopharma in San Francisco announced a new partnership to collaborate on the production of antibody drug conjugates (ADCs) for undisclosed cancerous targets.

  10. Avanir’s Drug Combination Reduces Agitation in Alzheimer’s Disease Patients
    9/18/2014

    Avanir Pharmaceuticals this week announced the positive results from its phase 2 clinical trial for its combination drug therapy AVP-923, which was successful in lowering agitation in patients with Alzheimer's disease.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.